The CPRIT grant supporting Wittung-Stafshede’s appointment is part of a broader $67 million investment by the agency to fund cutting-edge cancer research across Texas institutions. This funding surge aims to accelerate scientific discovery in cancer prevention, diagnosis, and therapy. Wittung-Stafshede’s expertise lies at the crucial intersection of biophysics, metalloprotein chemistry, and cancer metastasis, making her an invaluable asset for Rice’s drive to deepen its biomedical research capabilities.

Wittung-Stafshede’s prior tenure at Rice as an associate professor of biosciences between 2004 and 2008 laid the foundation for her enduring connection to the university. She expressed enthusiasm for her return, highlighting the unparalleled collaborative environment Rice offers, especially through proximity to the Texas Medical Center, one of the world’s foremost biomedical hubs. This environment promises fertile ground for interdisciplinary synergies bridging chemistry, biology, and clinical research.

Central to Wittung-Stafshede’s scientific inquiry is the study of metalloproteins—protein molecules that bind metal ions such as copper, fundamental to maintaining cellular homeostasis. Her research elucidates the paradoxical role these proteins play in cancer progression. While essential to normal physiology, copper-binding metalloproteins can inadvertently facilitate tumor metastasis by supplying copper, a trace element pivotal for angiogenesis and cellular proliferation in malignant tissues.

Employing an array of sophisticated biochemical and spectroscopic methodologies, her laboratory interrogates the molecular mechanisms underpinning protein-metal interactions. Through spectroscopic techniques like circular dichroism, electron paramagnetic resonance, and nuclear magnetic resonance, her group deciphers the conformational dynamics and metal coordination chemistry that govern protein function and pathological aggregation.

One of the more profound implications of Wittung-Stafshede’s work is the potential to identify novel molecular targets that disrupt copper-dependent pathways exploited by metastatic cancer cells. By unraveling precisely how copper ions modulate the structural and functional properties of these proteins within cancerous environments, her research opens avenues for the design of inhibitors that could arrest metastasis, the leading cause of cancer mortality.

Beyond individual cancer types, Wittung-Stafshede’s research suggests that perturbations in copper metabolism may represent a unifying hallmark across diverse malignancies. This insight raises the tantalizing prospect of developing broad-spectrum anti-metastatic therapies grounded in fundamental bioinorganic chemistry, transcending traditional tumor classification paradigms.

In addition to her cancer-focused investigations, Wittung-Stafshede is deeply engaged with the molecular underpinnings of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Here, the spotlight shifts to metal-binding proteins that undergo pathological aggregation into amyloid fibrils—misfolded protein assemblies implicated in neuronal toxicity and cell death. Her work probes the mechanisms by which metal ions influence amyloid formation, morphology, and toxicity.

A fundamental enigma in neurodegeneration is why certain proteins begin aggregating and how different amyloid conformations emerge. Wittung-Stafshede emphasizes the necessity of basic mechanistic understanding to unravel triggers underpinning metal-induced amyloidogenesis, without which rational therapeutic intervention remains elusive. Her multidisciplinary approach integrates biophysical characterization with cellular models to illuminate these processes.

Since 2015, Wittung-Stafshede has held a professorship in the Chemical Biology division at Chalmers University of Technology in Sweden, where she also served as division head, fostering excellence in faculty development and gender equality initiatives. Her leadership and prolific scholarly output—exceeding 270 peer-reviewed publications—position her at the forefront of protein chemistry and biomedical research internationally.

Her scientific acumen is further evidenced by her membership on the Nobel Committee for Chemistry since 2020, reflecting her stature within the scientific community. Her career has been marked by pivotal faculty roles in prestigious institutions across North America and Europe, shaping the landscape of molecular life sciences through both research and mentoring.

CPRIT was established through visionary legislative and public support in Texas, reflecting a commitment to making the state a nexus for cancer innovation. Since its inception and latest funding expansion, the agency has deployed more than $3.7 billion in grants and successfully recruited over 300 leading researchers, including Wittung-Stafshede, solidifying Texas as a global leader in cancer research.

Pernilla Wittung-Stafshede’s appointment at Rice represents not just a faculty hire but a strategic enhancement of the university’s ability to tackle some of the most intractable challenges in cancer and neurodegeneration. Her integrative, mechanism-driven approach to biophysics and protein chemistry stands to yield groundbreaking insights with profound translational implications, driving forward the frontiers of science and medicine.

Subject of Research: Molecular mechanisms of cancer metastasis and neurodegenerative diseases focusing on metalloproteins and amyloid aggregation.

Article Title: Renowned Biophysicist Pernilla Wittung-Stafshede Joins Rice University with $6 Million CPRIT Grant to Advance Cancer and Neurodegeneration Research

Web References:
– https://cprit.texas.gov/grants-funded
– https://www.cprit.texas.gov/news-events/articles/state-cancer-agency-awards-68-million-in-research-grants-to-texas-institutions/

Image Credits: Photo by Johan Wingborg

Since 2010, CPRIT has channeled a substantial $167 million into UT Health San Antonio, underscoring the institution’s unwavering commitment to advancing cancer science. The latest funding allocation prioritizes expansion of core laboratory facilities equipped with revolutionary technologies unmatched anywhere else in the state. In particular, over $2.4 million will be devoted to enhancing infrastructure aimed at identifying novel therapeutic targets and developing advanced modalities to treat stubborn, therapy-resistant cancers.

A distinctive aspect of this funding round is its innovative approach to addressing the vexing challenge of drug resistance in oncology. UT Health San Antonio’s laboratories will harness state-of-the-art tools, including an arrayed CRISPR knockout screening system—enabling comprehensive target identification and validation—and a small molecule degrader (SMD) discovery platform designed to tackle so-called “undruggable” proteins. These proteins have historically evaded conventional therapies due to structural or functional complexities, but emerging technologies promise to open new avenues for drug development.

Dr. Daohong Zhou, tenured professor in Biochemistry and Structural Biology and a lead figure at UT Health San Antonio’s Joe R. and Teresa Lozano Long School of Medicine, will helm this strategic expansion. As director of the Target Discovery Core at the Greehey Children’s Cancer Research Institute and associate director for drug development at the Mays Cancer Center, Dr. Zhou is uniquely positioned to advance translational research that bridges laboratory breakthroughs with clinical applications. His vision centers on overcoming the absence of integrated Target Identification and Validation (TIV) facilities within Texas, a void that has previously restricted local drug discovery efforts.

The deployment of these innovative TIV technologies promises a paradigm shift in how researchers dissect cancer biology and identify actionable molecular targets. Arrayed CRISPR knockout screening offers unparalleled resolution to systematically deactivate genes and assess their role in oncogenesis and drug resistance. Complementing this, the small molecule degrader platform enables the screening of compounds that can selectively induce degradation of pathogenic proteins, a cutting-edge tactic that holds enormous therapeutic potential for malignancies that defy standard treatment protocols.

Parallel to these laboratory-focused endeavors, UT Health San Antonio is also spearheading community-level cancer prevention efforts by addressing vaccination disparities related to HPV—a virus implicated in numerous cancers affecting both men and women. Dr. Erika L. Thompson, associate professor at The University of Texas School of Public Health San Antonio, has secured a CPRIT prevention grant to implement a culturally tailored, bilingual community-based intervention aimed at increasing HPV vaccine uptake among adolescents in Bexar County, Texas.

This intervention builds on the evidence-based “All for Them” vaccination program, adapting its proven social marketing and outreach strategies for local populations. Collaborations with UT Health San Antonio’s School of Nursing and community organizations ensure that vaccines are administered within trusted environments such as after-school programs, leveraging community health workers to overcome barriers related to healthcare access, vaccine hesitancy, and misinformation. By prioritizing underserved communities, the program endeavors to narrow health disparities while substantially reducing the incidence of HPV-related cancers over time.

The scientific rigor and community engagement embedded in this multifaceted program illuminate the broader role of public health science in cancer prevention. As Dr. Thompson emphasizes, elevating vaccine demand, facilitating access, and cultivating trust constitute essential pillars for effective cancer risk reduction. The partnership with The University of Texas at San Antonio amplifies interdisciplinary collaboration, reinforcing regional capacities for impactful health interventions.

UT Health San Antonio’s dual focus on advanced biomedical research and pragmatic community outreach reflects the university’s recent classification as a Research 1 (R1) institution, an elite designation bestowed by the American Council on Education and the Carnegie Foundation. Ranking in the top 5% of U.S. universities for research activity, UT Health San Antonio exemplifies how integrated scientific discovery and public health innovation can jointly propel cancer control efforts.

The institution’s Mays Cancer Center, one of only four National Cancer Institute-designated centers in Texas, serves as a crucible for translational oncology research and clinical excellence. Since 2017, its partnership with MD Anderson Cancer Center has extended access to pioneering cancer treatments, delivering state-of-the-art care to South Texas patients without necessitating long-distance travel. These collaborations underscore a comprehensive ecosystem where cutting-edge laboratory discoveries, clinical trials, and community-focused programs converge to redefine cancer prevention and therapy.

By acquiring and operationalizing next-generation technological platforms within its core facilities, UT Health San Antonio is poised to accelerate drug discovery pipelines for formidable cancers such as brain tumors and soft tissue sarcomas, which have traditionally shown resistance to conventional treatments. These advancements offer hope for the development of innovative pharmacological agents capable of targeting elusive molecular mechanisms critical to tumor survival and progression.

Simultaneously, the community-based HPV vaccination program exemplifies how evidence-driven, culturally sensitive interventions can dramatically enhance preventive healthcare uptake in populations that have historically faced vaccine access challenges. Through collective efforts of multidisciplinary teams, including epidemiologists, public health practitioners, nursing professionals, and community advocates, these programs set new standards for equitable cancer prevention strategies.

The CPRIT funding thus marks a significant milestone for UT Health San Antonio, reaffirming its status as a powerhouse in cancer research and public health intervention. The integration of rigorous scientific inquiry with actionable community programs illustrates a holistic approach to cancer control—one where benchside innovation synchronizes with bedside and community impacts.

As Texas contends with significant cancer morbidity and mortality burdens, the work undertaken at UT Health San Antonio offers an inspiring blueprint for leveraging state resources, technological innovation, and community partnerships to transform the landscape of oncological care and prevention not only locally but across the nation.

Subject of Research: Cancer therapeutics targeting drug resistance; HPV vaccination and cancer prevention.

Article Title: UT Health San Antonio Advances Cancer Research and HPV Prevention with CPRIT Funding

News Publication Date: June 18, 2025

Web References:
– https://uthscsa.edu/
– https://cancer.uthscsa.edu/

Keywords: Cancer, Cancer treatments, Cancer medication, Viruses, Vaccination, Medical technology, Laboratory equipment

MD Anderson’s chief scientific officer, Giulio Draetta, M.D., Ph.D., emphasized the strategic importance of CPRIT’s continued financial support, framing it as a catalyst for the institution’s mission to eradicate cancer. Draetta highlighted the rigorous dedication of MD Anderson’s scientists and clinicians whose collective expertise drives new paradigms in cancer biology, immunotherapy, and precision medicine. This award is not merely financial backing but a recognition of the potential impact of these evolving research programs poised to redefine contemporary oncology.

Since CPRIT’s inception, it has invested over $3.9 billion into cancer research statewide, a staggering infusion of resources aimed at elevating Texas as a global hub for life sciences. MD Anderson alone has garnered more than $696 million, accounting for nearly 18% of CPRIT’s total awards, illustrating the center’s unmatched excellence and influence. The breadth of CPRIT’s distribution extends across 151 entities including academic bodies, nonprofits, and private firms, all aiming to enhance public health, strengthen scientific infrastructure, and invigorate the state’s economic prospects through advanced cancer research.

Among the distinguished research projects funded, the study of extracellular vesicles and exosomes under the stewardship of Raghu Kalluri, M.D., Ph.D., epitomizes cutting-edge cellular biology efforts. These nano-sized vesicles serve as critical mediators of intercellular communication and have garnered intense interest for their role in tumor progression, metastasis, and immune modulation. Kalluri’s work aims to unravel the molecular mechanisms governing exosome biogenesis and cargo transfer, potentially unlocking novel diagnostic markers or therapeutic targets in oncology.

Another pivotal research trajectory targets the implementation of germline genetic testing among prostate cancer patients within diverse, safety-net hospital environments. Led by Debanjan Pain, M.D., this initiative addresses an urgent clinical gap: increasing patient access to precision oncology diagnostics to identify hereditary cancer risk factors. By enhancing the uptake of genetic screening in underserved populations, this project aspires to democratize personalized medicine and improve prognostic and treatment decision-making in prostate cancer care.

Innovative immunotherapeutic approaches are at the core of Chibawanye Ene, M.D., Ph.D.’s investigation into glioblastoma, an aggressive brain malignancy notoriously resistant to conventional treatment. Ene’s research explores the therapeutic potential of genetically engineered macrophages designed to amplify the efficacy of immune checkpoint inhibitors. This approach seeks to reprogram the tumor microenvironment’s innate immune compartments, rekindling anti-tumor immune responses that could ultimately overcome glioblastoma’s immunosuppressive barriers.

In an equally novel endeavor, Isabella Glitza Oliva, M.D., Ph.D., is conducting an early-phase clinical study evaluating intrathecal adoptive immunotherapy employing autologous CD+ antigen-specific T cells in melanoma patients suffering from leptomeningeal disease. This targeted delivery of cellular therapy into the cerebrospinal fluid represents a pioneering stride toward combating this devastating complication characterized by widespread tumor spread within the central nervous system.

The exploration of microbial-inspired antibody toxin bioconjugates for cancer immunotherapy, led by Betty Kim, M.D., Ph.D., reflects a sophisticated convergence of molecular engineering and immunology. By harnessing microbial motifs to direct potent immune toxins selectively to cancer cells, this project aims to overcome immune evasion tactics employed by tumors, ushering in new classes of highly specific and efficacious therapeutics with reduced systemic toxicity.

Beyond these substantial academic projects, CPRIT’s unprecedented $16 million allocation to recruit six CPRIT Scholars denotes deliberate investment in human capital. This strategic recruitment drive will infuse MD Anderson’s faculty ranks with visionary researchers poised to spearhead transformative cancer research over the coming years. These scholars are expected to pioneer novel scientific inquiries, elevate collaborative interdisciplinary efforts, and ultimately translate laboratory discoveries into clinical applications that enhance patient outcomes.

The trajectory set forth by these research endeavors reflects an integrated, multi-dimensional strategy encompassing molecular biology, genetics, immunotherapy, and clinical innovation. MD Anderson’s ability to translate these complex scientific insights into tangible medical advances reiterates the seamless synergy between basic discovery and clinical impact. The CPRIT funding will undeniably accelerate timelines for breakthroughs, fortifying both the scientific community and patient care paradigms.

Moreover, the broader implications of CPRIT’s support extend well beyond academic research. The infusion of these funds stimulates economic growth, nurtures biotechnology development, and fosters educational opportunities within Texas. The initiative amplifies the state’s standing as a fertile environment for life sciences innovation, supporting ecosystems that catalyze high-impact science while generating jobs and improving public health infrastructures.

In sum, this latest CPRIT grant embodies a profound commitment to conquering cancer through multidisciplinary excellence and scientific rigor. MD Anderson’s researchers stand on the vanguard of a new era, propelled by fresh funding streams, global collaborative networks, and cutting-edge technologies. Their relentless pursuit of knowledge and therapeutic innovation promises to transform cancer treatment landscapes in Texas and around the world, heralding hope for patients and families confronting cancer’s enormous burden.

Subject of Research: Cancer Research, including exosomes biology, germline genetic testing uptake, immunotherapy for glioblastoma and melanoma, and antibody toxin bioconjugates.

Article Title: MD Anderson Secures $21.4 Million CPRIT Grant to Propel Breakthroughs in Cancer Research and Faculty Recruitment

News Publication Date: May 21, 2025

Web References:

• https://www.mdanderson.org/
• https://faculty.mdanderson.org/profiles/giulio_draetta.html
• https://faculty.mdanderson.org/profiles/raghu_kalluri.html
• https://faculty.mdanderson.org/profiles/debanjan_pain.html
• https://faculty.mdanderson.org/profiles/chibawanye_ene.html
• https://faculty.mdanderson.org/profiles/isabella_glitza.html
• https://faculty.mdanderson.org/profiles/yonsonbetty_kim.html

Keywords: Cancer Research, Neurosurgery, Exosomes, Immune Response, Immune System, Immunotherapy, Prostate Cancer